Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Long Island University currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners and 1 distinct art unit. This structure indicates that the university's pending biotechnology applications are being reviewed within the same art unit by different staff. Such a concentration suggests that the subject matter of the 2 pending actions is technically similar enough to fall under the same administrative group.
MARTIN, KEVIN STEPHEN is the busiest examiner for the university, with 1 pending office action. The workload is distributed such that each of the 2 distinct examiners handles one of the 2 pending actions. For the practitioner, this means that while the technical environment of the 1 distinct art unit is consistent, the specific preferences of 2 different examiners must be addressed. This balance of a single art unit and 2 distinct examiners allows for some technical consistency across the university's pending Biotechnology & Pharmaceuticals matters.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MARTIN, KEVIN STEPHEN | 1 | 77.2% | +23.2% |
| SZNAIDMAN, MARCOS L | 1 | 37.3% | +16.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18729847 | SYNTHESIS OF BORON-CONTAINING AMIDOXIME REAGENTS AND THEIR APPLICATION TO SYNTHESIZE FUNCTIONALIZED OXADIAZOLE AND QUINAZOLINONE DERIVATIVES | MARTIN, KEVIN STEPHEN | — |
| 18691500 | KCa3.1 INHIBITORS FOR PODOCYTE PROTECTION | SZNAIDMAN, MARCOS L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18729847 | SYNTHESIS OF BORON-CONTAINING AMIDOXIME REAGENTS AND THEIR APPLICATION TO SYNTHESIZE FUNCTIONALIZED OXADIAZOLE AND QUINAZOLINONE DERIVATIVES | MARTIN, KEVIN STEPHEN | — |
| 18691500 | KCa3.1 INHIBITORS FOR PODOCYTE PROTECTION | SZNAIDMAN, MARCOS L | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18729847 | SYNTHESIS OF BORON-CONTAINING AMIDOXIME REAGENTS AND THEIR APPLICATION TO SYNTHESIZE FUNCTIONALIZED OXADIAZOLE AND QUINAZOLINONE DERIVATIVES | MARTIN, KEVIN STEPHEN | — | §103§112 | Non-Final OA | — | Pending | Jul 17, 2024 |
| 18691500 | KCa3.1 INHIBITORS FOR PODOCYTE PROTECTION | SZNAIDMAN, MARCOS L | 1628 | §102§112 | Non-Final OA | — | Pending | Mar 13, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial